SECsense Logo

AstraZeneca PLC Financial Report: Voting Rights & Compliance Update

$AZN
Form 6-K
Filed on: 2025-10-01
Source
AstraZeneca PLC Financial Report: Voting Rights & Compliance Update

The key information extracted from the provided financial report (Form 6-K) regarding AstraZeneca PLC is as follows:

  1. Company Overview:
  • Name: AstraZeneca PLC
  • Headquarters Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
  • Business Focus: The company specializes in the discovery, development, and commercialization of prescription medicines, particularly in Oncology, Rare Diseases, and various biopharmaceutical areas including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
  1. Total Voting Rights:
  • As of September 30, 2025, AstraZeneca PLC has issued share capital with voting rights consisting of 1,550,701,945 ordinary shares, each with a nominal value of US$0.25.
  • There are no shares held in Treasury.
  • This total number of voting rights (1,550,701,945) serves as the denominator for shareholders to determine their reporting obligations under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
  1. Regulatory Filing Information:
  • This report is filed in compliance with the Securities Exchange Act of 1934.
  • The company's Commission File Number is 001-11960.
  • The filing indicates that AstraZeneca PLC is submitting the report under Form 20-F.
  1. Submission Date:
  • The report is dated October 1, 2025.
  1. Contact Information:
  • The Company Secretary is Matthew Bowden.
  1. Nature of Disclosure:
  • The notification complies with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.

This report provides essential insights into AstraZeneca's voting rights structure, relevant regulatory compliance, and contact details for investor relations, which may be crucial for investors and stakeholders monitoring the company’s governance and market position.